Current issue
Archive
Videos
Articles in press
About the journal
Supplements
Editorial board
Reviewers
Abstracting and indexing
Subscription
Contact
Instructions for authors
Publication charge
Ethical standards and procedures
Editorial System
Submit your Manuscript
|
2/2007
vol. 109 abstract:
Original paper
Intravitreal triamcinolone acetonide injections in treatment of cystoid macular edema due to diabetic maculopathy
Anna Lubczyńska
1
,
Jarosław Kocięcki
1
Klinika Oczna 2007, 109 (2): 165-168
Online publish date: 2007/06/12
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Purpose
To appoint the most adequate follow-up parameter of intravitreal TA injections in CME treatment due to diabetic maculopathy and to find the most reliable treatment scheme Material and method: 4 mg (in 0,1 ml) of crystalline TA were injected into the vitreous of 17 eyes. Results There was a statistically significant improvement of BCVA for distance and near vision. There was statistically significant difference in retinal thickness outcomes measured at baseline and at the end of the follow-up by both OCT and RTA No correlation of BCVA changes and retinal thickness changes measured in OCT and RTA was found. Conclusions Intravitreal TA administration seems to be an effective method of treatment in diabetic CME. OCT is the most adequate method of follow-up of intravitreal TA injections in treatment of CME due to diabetic maculopathy. RTA and FA changes analysis are alternative monitoring methods. Dosage of 4mg TA in 0.1 ml seems to be sufficient. In cases of CME recurrence subsequent intravitreal injection in the first 6 month after initial injection seems to unnecessary. keywords:
diabetic maculopathy, cystoid macula edema, triamcinolone acetonide |
|